Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
Authors:
- 15 June 2022
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 83 (2) , 163-172
Abstract
No abstract availableKeywords
Funding Information
- Renji Hospital (PYII20-11)
- National Natural Science Foundation of China (82173826)
This publication has 33 references indexed in Scilit:
- The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular TumoursEuropean Urology, 2016
- Fumarate Hydratase–deficient Renal Cell Carcinoma Is Strongly Correlated With Fumarate Hydratase Mutation and Hereditary Leiomyomatosis and Renal Cell Carcinoma SyndromeAmerican Journal of Surgical Pathology, 2016
- Preoperative Evaluation of Renal Cell Carcinoma by Using 18F-FDG PET/CTClinical Nuclear Medicine, 2015
- FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0European Journal of Nuclear Medicine and Molecular Imaging, 2014
- Hereditary leiomyomatosis and renal cell cancer (HLRCC): renal cancer risk, surveillance and treatmentFamilial Cancer, 2014
- The Glycolytic Shift in Fumarate-Hydratase-Deficient Kidney Cancer Lowers AMPK Levels, Increases Anabolic Propensities and Lowers Cellular Iron LevelsCancer Cell, 2011
- Aberrant succination of proteins in fumarate hydratase‐deficient mice and HLRCC patients is a robust biomarker of mutation statusThe Journal of Pathology, 2011
- Novel FH mutations in families with hereditary leiomyomatosis and renal cell cancer (HLRCC) and patients with isolated type 2 papillary renal cell carcinomaJournal of Medical Genetics, 2011
- Exploring a glycolytic inhibitor for the treatment of an FH-deficient type-2 papillary RCCNature Reviews Urology, 2011
- Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancerNature Genetics, 2002